SRR23303730
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.170
- APICAL_SURFACE+0.150
- APICAL_JUNCTION+0.080
- KRAS_SIGNALING_DN+0.070
- UV_RESPONSE_UP+0.070
- COAGULATION+0.040
- MYOGENESIS+0.040
- PEROXISOME+0.040
- WNT_BETA_CATENIN_SIGNALING+0.020
- ESTROGEN_RESPONSE_EARLY+0.010
Top 10 suppressed
- PROTEIN_SECRETION-0.440
- E2F_TARGETS-0.390
- G2M_CHECKPOINT-0.360
- MTORC1_SIGNALING-0.360
- PANCREAS_BETA_CELLS-0.350
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.330
- UV_RESPONSE_DN-0.310
- KRAS_SIGNALING_UP-0.280
- ALLOGRAFT_REJECTION-0.270
- MITOTIC_SPINDLE-0.250
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG559 | — | — | 0.835 |
| 2 | R84 | — | — | 0.810 |
| 3 | R88 | — | — | 0.805 |
| 4 | TCGA-E7-A7DU-01A-11R-A32O-07 | — | — | 0.795 |
| 5 | MNG656 | — | — | 0.793 |
| 6 | R87 | — | — | 0.792 |
| 7 | TCGA-EW-A423-01A-11R-A24H-07 | — | B | 0.785 |
| 8 | MNG1250 | — | — | 0.782 |
| 9 | 544499d8-b5a8-4ed8-ae99-6f7a504530e7 | — | — | 0.780 |
| 10 | SRR1404168 | GTEX | — | 0.777 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.170 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.150 | Temsirolimus | — uncovered |
| APICAL_JUNCTION | 0.080 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.070 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.070 | Idelalisib | — uncovered |
| COAGULATION | 0.040 | Binimetinib | — uncovered |
| MYOGENESIS | 0.040 | Inavolisib | — uncovered |
| PEROXISOME | 0.040 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.020 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.010 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.010 | Inavolisib | — uncovered |